

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL |    | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|----------|-------------|
|                     | AA |                 |      |      |       |          |             |
|                     | AB |                 |      |      |       |          |             |
|                     | AC |                 |      |      |       |          |             |
|                     | AD |                 |      |      |       |          |             |
|                     | AE |                 |      |      |       |          |             |
|                     | AF |                 |      |      |       |          |             |
|                     | AG |                 |      |      |       |          |             |
|                     | AH |                 |      |      |       |          |             |
|                     | AI |                 |      |      |       |          |             |
|                     | AJ |                 |      |      |       |          |             |
|                     | AK |                 |      |      |       |          |             |
|                     | AL |                 |      |      |       |          |             |

## FOREIGN PATENT DOCUMENTS

|  |    | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRANSLATION              |                          |
|--|----|-----------------|------|--------|-------|----------|--------------------------|--------------------------|
|  |    |                 |      |        |       |          | YES                      | NO                       |
|  | AM |                 |      |        |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | AN |                 |      |        |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | AO |                 |      |        |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | AP |                 |      |        |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | AQ |                 |      |        |       |          | <input type="checkbox"/> | <input type="checkbox"/> |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|        |    |   |
|--------|----|---|
| /B.P./ | AR | Houghton et al., "Imatinib mesylate (STI571, Gleevec) is a potent inhibitor of BCRP (ABCG2) and reverses topotecan resistance in vitro," Abstract No. 1959, Proceedings of the American Association for Cancer Research, Vol. 44, March (2003) Abstract |
| /B.P./ | AS | Litman et al., "From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance," Cellular and Molecular Life Sciences, Vol. 58, pp. 931-959 (2001)  |
| /B.P./ | AT | Lage et al., "Effect of the breast-cancer resistance protein on atypical multidrug resistance," The Lancet Oncology, Vol. 1, pp. 169-75 (2000)  |

|          |                    |                 |            |
|----------|--------------------|-----------------|------------|
| EXAMINER | /Benjamin Packard/ | DATE CONSIDERED | 01/10/2008 |
|----------|--------------------|-----------------|------------|

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|        |    |   |
|--------|----|---|
| /B.P./ | DA | Ross D.D., "Novel mechanisms of drug resistance in leukemia," Leukemia, Vol. 14, pp. 467-473 (2000)   |
| /B.P./ | DB | Wu et al., "Drug-resistant proteins in breast cancer: recent progress in multidrug resistance," Ai Zheng, Vol. 22(4), pp. 441-4 (2003) Abstract   |
| /B.P./ | DC | Tan et al., "Multidrug resistance transporters and modulation," Current Opinion in Oncology 2000, Vol. 12, pp. 450-458 (2000)   |
| /B.P./ | DD | Kawabata et al., "Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells," Biochemical and Biophysical Research Communications, Vol. 280, pp. 1216-1223 (2001)   |
| /B.P./ | DE | Erllichman et al., "The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux," Cancer Research, Vol. 61, pp. 739-748 (2001) |
| /B.P./ | DF | Sparreboom et al., "Pharmacogenomics of ABC transporters and its role in cancer chemotherapy," Drug Resistance Updates 6, pp. 71-84 (2003)  |
|        | DG |   |
|        | DH |   |
|        | DI |   |
|        | DJ |   |
|        | DK |   |
|        | DL |   |
|        | DM |   |
|        | DN |   |

EXAMINER

/Benjamin Packard/

DATE CONSIDERED

01/10/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.